Cancer Cell:S1PR1-STAT3激活促进骨髓样细胞的促肿瘤转移作用

2012-05-24 Victor 生物谷

近来研究表明,骨髓样细胞可使远处器官易于接受扩散肿瘤细胞的集落形成。然而,其具体机制一直不明。5月14日Cancer Cell报道了Hua Yu研究组的论文"S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites"揭示了其分子机制。   研究者发现,在肿瘤细胞中

近来研究表明,骨髓样细胞可使远处器官易于接受扩散肿瘤细胞的集落形成。然而,其具体机制一直不明。5月14日Cancer Cell报道了Hua Yu研究组的论文"S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites"揭示了其分子机制。

 

研究者发现,在肿瘤细胞中神经鞘氨醇-1-磷酸化受体-1(S1PR1)-STAT3信号通路上调可激活肿瘤转移靶部位细胞的S1PR1-STAT3水平,在机体远处组织造成易于接受转移肿瘤的微环境。抑制S1PR1或者STAT3在骨髓样细胞中的功能可破坏已存在的易转移微环境。

 

S1PR1-STAT3信号通路的激活使骨髓样细胞能穿过血管,在远处器官形成利于肿瘤转移的微环境并且介导其自身及其他基质细胞持续的存活和增殖。对肿瘤患者不含肿瘤细胞的淋巴结的分析发现,与正常人的淋巴结细胞相比,肿瘤患者的标本呈现更高的骨髓样细胞浸润,STAT3的高水平活化以及细胞存活信号的增强。生物谷Bioon.com)

doi: 10.1016/j.ccr.2012.03.039
PMC:

PMID:

S1PR1-STAT3 Signaling Is Crucial for Myeloid Cell Colonization at Future Metastatic Sites

Jiehui Deng, Yong Liu, Heehyoung Lee, Andreas Herrmann, Wang Zhang, Chunyan Zhang, Shudan Shen, Saul J. Priceman, Maciej Kujawski, Sumanta K. Pal, Andrew Raubitschek, Dave S.B. Hoon, Stephen Forman, Robert A. Figlin, Jie Liu, Richard Jove, Hua Yu

Recent studies underscore the importance of myeloid cells in rendering distant organs hospitable for disseminating tumor cells to colonize. However, what enables myeloid cells to have an apparently superior capacity to colonize distant organs is unclear. Here, we show that S1PR1-STAT3 upregulation in tumor cells induces factors that activate S1PR1-STAT3 in various cells in premetastatic sites, leading to premetastatic niche formation. Targeting either S1PR1 or STAT3 in myeloid cells disrupts existing premetastatic niches. S1PR1-STAT3 pathway enables myeloid cells to intravasate, prime the distant organ microenvironment and mediate sustained proliferation and survival of their own and other stromal cells at future metastatic sites. Analyzing tumor-free lymph nodes from cancer patients shows elevated myeloid infiltrates, STAT3 activity, and increased survival signal.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958745, encodeId=e4af1958e458f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 04 14:58:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868514, encodeId=66971868514da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 21 23:58:00 CST 2012, time=2012-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941177, encodeId=ae9b19411e7a5, content=<a href='/topic/show?id=229116e55b8' target=_blank style='color:#2F92EE;'>#STAT3激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16755, encryptionId=229116e55b8, topicName=STAT3激活)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Tue Jan 29 04:58:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780571, encodeId=ee951e805719c, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jun 03 03:58:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291602, encodeId=f0781291602a9, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348949, encodeId=ef7d134894995, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
    2012-07-04 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958745, encodeId=e4af1958e458f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 04 14:58:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868514, encodeId=66971868514da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 21 23:58:00 CST 2012, time=2012-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941177, encodeId=ae9b19411e7a5, content=<a href='/topic/show?id=229116e55b8' target=_blank style='color:#2F92EE;'>#STAT3激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16755, encryptionId=229116e55b8, topicName=STAT3激活)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Tue Jan 29 04:58:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780571, encodeId=ee951e805719c, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jun 03 03:58:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291602, encodeId=f0781291602a9, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348949, encodeId=ef7d134894995, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958745, encodeId=e4af1958e458f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 04 14:58:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868514, encodeId=66971868514da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 21 23:58:00 CST 2012, time=2012-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941177, encodeId=ae9b19411e7a5, content=<a href='/topic/show?id=229116e55b8' target=_blank style='color:#2F92EE;'>#STAT3激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16755, encryptionId=229116e55b8, topicName=STAT3激活)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Tue Jan 29 04:58:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780571, encodeId=ee951e805719c, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jun 03 03:58:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291602, encodeId=f0781291602a9, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348949, encodeId=ef7d134894995, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958745, encodeId=e4af1958e458f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 04 14:58:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868514, encodeId=66971868514da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 21 23:58:00 CST 2012, time=2012-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941177, encodeId=ae9b19411e7a5, content=<a href='/topic/show?id=229116e55b8' target=_blank style='color:#2F92EE;'>#STAT3激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16755, encryptionId=229116e55b8, topicName=STAT3激活)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Tue Jan 29 04:58:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780571, encodeId=ee951e805719c, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jun 03 03:58:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291602, encodeId=f0781291602a9, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348949, encodeId=ef7d134894995, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958745, encodeId=e4af1958e458f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 04 14:58:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868514, encodeId=66971868514da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 21 23:58:00 CST 2012, time=2012-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941177, encodeId=ae9b19411e7a5, content=<a href='/topic/show?id=229116e55b8' target=_blank style='color:#2F92EE;'>#STAT3激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16755, encryptionId=229116e55b8, topicName=STAT3激活)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Tue Jan 29 04:58:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780571, encodeId=ee951e805719c, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jun 03 03:58:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291602, encodeId=f0781291602a9, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348949, encodeId=ef7d134894995, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1958745, encodeId=e4af1958e458f, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Jul 04 14:58:00 CST 2012, time=2012-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868514, encodeId=66971868514da, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Fri Dec 21 23:58:00 CST 2012, time=2012-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941177, encodeId=ae9b19411e7a5, content=<a href='/topic/show?id=229116e55b8' target=_blank style='color:#2F92EE;'>#STAT3激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16755, encryptionId=229116e55b8, topicName=STAT3激活)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Tue Jan 29 04:58:00 CST 2013, time=2013-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780571, encodeId=ee951e805719c, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sun Jun 03 03:58:00 CST 2012, time=2012-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291602, encodeId=f0781291602a9, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348949, encodeId=ef7d134894995, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
    2012-05-26 李研东

相关资讯

Cancer Res:科学家发现驱动恶性肿瘤生长和存在的关键激酶

为了更好地理解恶性肿瘤(肉瘤,sarcomas)的信号通路,近日,来自莫非特癌症研究中心的研究者使用先进的基于蛋白质组学的质谱分析法对一组蛋白质酶的特性进行分析,这组酶在癌症生物学中扮演者重要的开关作用。研究者发现一种酪氨酸激酶可以驱动(driver)恶性肿瘤的生长和生存。相关研究成果刊登在了近日的国际杂志Cancer Research上。 一般的癌症(carcinomas)来源于上皮细胞,

Pediatrics:叶酸或许可以减少儿童罹患某些癌症

含叶酸食品或许可减少最常见的肾细胞癌症类型和一种儿童脑肿瘤癌症类型的发病率,由美国明尼苏达大学博士后研究员Kimberly J. Johnson博士带领完成的一项研究证实了这一观点。 自1998年以来,FDA已责成推广含叶酸食物,因为早先的研究已经表明产前孕妇消耗叶酸的话能显著降低婴儿神经管缺陷的发病率。 Johnson表示:这项研究是迄今为止规模最大的相关研究,研究证实了叶酸也可以降低美国儿

Cancer cell:基底样乳腺癌的新组合治疗策略

多个研究项目包括2006年北卡罗莱纳大学教堂山分校进行的研究已采用DNA芯片分析技术,找出了几个乳腺癌亚型包括管状A型(luminal A)、管状B型,(luminal B)、基底样型和Her-2过度表达型。目前正在开发较简单的测试技术,以帮助医生确定这些亚型。近来,这些测试技术已帮助多项研究证实了基底样或三阴性乳腺癌可能在非裔美国人比白种人更流行更普遍。 UNC莱恩伯格科学家Charles

Science:研究者揭示抑制癌症的新靶点PARP-1

5月11日,刊登在国际著名杂志Science上的一项研究阐明了一种DNA损伤检测酶PARP-1,当这种酶被抑制后,可以有效抵御癌症和其它疾病。来自托马斯杰佛逊大学和杰佛逊金梅尔癌症中心的研究者揭示了新的靶点,包括特殊的锌指结构域,从而来使得特殊药物作用于PARP-1使其丧失活性。研究者希望发现更多副作用较小的特殊PARP-1的抑制子来达到抑制PARP-1的目的,抑制PARP-1的药物目前已证实在治

乳腺癌干细胞研究进展

乳腺癌干细胞的分子特征,图片来自互动百科。 癌症起源于人体内一些发生突变的细胞,而且随后其中一些不断发生突变,导致逃避体内免疫系统的监控,同时不受控制地生长。如今,癌症已经成为人类面临着的一大灾难。更令人讨厌的是,癌症病人经过常规的化疗和放疗治疗之后,常常会复发,而且造成的危害更加严重。鉴于此,科学家们提出癌干细胞是造成癌症转移和复发的根本原因。但是,对于癌干细胞是否存在,科学界一直存在争议。然

Gastroenterology :鱼类脂肪酸或可降低肝癌风险

近日,6月刊的《胃肠病学》(Gastroenterology )发表的一项以人口为基础的日本成人研究显示,食用富含n-3多不饱和脂肪酸(n-3 PUFA)的鱼类以及二十碳五烯酸(EPA)、二十二碳五烯酸(DPA)和二十二碳六烯酸(DHA)等n-3 PUFA与肝细胞癌(HCC)发生风险呈剂量依赖性负相关。 长期以来,食用n-3 PUFA被认为可降低多种癌症的发生风险,但对肝癌预防作用的专门研究报道